Grace Therapeutics, Inc. Nonoperating Income (Expense) in USD from 2018 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Grace Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from 2018 to Q3 2025.
  • Grace Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending September 30, 2025 was $1.59M, a 191% increase year-over-year.
  • Grace Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending September 30, 2025 was $3.06M, a 68.1% increase year-over-year.
  • Grace Therapeutics, Inc. annual Nonoperating Income (Expense) for 2024 was $3.91M.
  • Grace Therapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was -$1.83M, a 1096% decline from 2022.
  • Grace Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was $184K, a 96.4% decline from 2021.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Growth (%)

Grace Therapeutics, Inc. Quarterly Nonoperating Income (Expense) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $3.06M $1.59M +$1.04M +191% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-13
Q2 2025 $2.02M -$272K -$1.89M -117% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-12
Q1 2025 $3.91M $2.8M +$3.59M Jan 1, 2025 Mar 31, 2025 10-K 2025-06-23
Q4 2024 $321K -$1.06M -$1.5M -338% Oct 1, 2024 Dec 31, 2024 10-Q 2025-02-13
Q3 2024 $1.82M $547K +$2.17M Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-13
Q2 2024 -$353K $1.62M +$1.48M +1042% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-12
Q1 2024 -$1.83M -$792K -$906K -795% Jan 1, 2024 Mar 31, 2024 10-K 2025-06-23
Q4 2023 -$927K $444K +$362K +441% Oct 1, 2023 Dec 31, 2023 10-Q 2025-02-13
Q3 2023 -$1.29M -$1.63M -$1.65M -6879% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 $362K $142K +$178K Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-09
Q1 2023 $184K $114K +$263K Jan 1, 2023 Mar 31, 2023 10-K 2024-06-21
Q4 2022 -$79K $82K -$614K -88.2% Oct 1, 2022 Dec 31, 2022 10-Q 2024-02-12
Q3 2022 $535K $24K -$4.52M -99.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 $5.06M -$36K -$63K -233% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-11
Q1 2022 $5.12M -$149K +$3.2M +95.5% Jan 1, 2022 Mar 31, 2022 10-K 2023-06-23
Q4 2021 $1.93M $696K +$1.95M Oct 1, 2021 Dec 31, 2021 10-Q 2023-02-14
Q3 2021 -$27K $4.55M +$2.66M +141% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$2.69M $27K +$572K Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$3.26M -$3.35M -$24M -116% Jan 1, 2021 Mar 31, 2021 10-K 2022-06-21
Q4 2020 $20.7M -$1.26M +$4.72M +79% Oct 1, 2020 Dec 31, 2020 10-Q 2022-02-14
Q3 2020 $16M $1.89M +$16.8M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$780K -$545K +$295K +35.1% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 -$1.08M $20.6M Jan 1, 2020 Mar 31, 2020 10-K 2021-06-22
Q4 2019 -$5.98M Oct 1, 2019 Dec 31, 2019 10-Q 2021-02-09
Q3 2019 -$14.9M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-16
Q2 2019 -$840K Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-13

Grace Therapeutics, Inc. Annual Nonoperating Income (Expense) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $3.91M +$5.75M Apr 1, 2024 Mar 31, 2025 10-K 2025-06-23
2023 -$1.83M -$2.02M -1096% Apr 1, 2023 Mar 31, 2024 10-K 2025-06-23
2022 $184K -$4.94M -96.4% Apr 1, 2022 Mar 31, 2023 10-K 2024-06-21
2021 $5.12M +$8.38M Apr 1, 2021 Mar 31, 2022 10-K 2023-06-23
2020 -$3.26M -$2.18M -203% Apr 1, 2020 Mar 31, 2021 10-K 2022-06-21
2019 -$1.08M +$3.89M +78.3% Apr 1, 2019 Mar 31, 2020 10-K 2021-06-22
2018 -$4.96M Apr 1, 2018 Mar 31, 2019 10-K 2020-06-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.